plozalizumab   Click here for help

GtoPdb Ligand ID: 8921

Synonyms: hu1D9 | MLN-1202 | MLN1202
Immunopharmacology Ligand
Compound class: Antibody
Comment: Plozalizumab is a humanised anti-CCR2 monoclonal antibody, being investigated for its anti-inflammatory actions [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis using the heavy and light chain variable amino acid sequences submitted with the INN record for plozalizumab, identifies 100% matches with sequences from patent US6696550 B2 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Horvath CJ, Rao PE. (2003)
Method of inhibiting stenosis and restenosis.
Patent number: US6663863 B2. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 17/01/2001. Publication date: 16/12/2003.
2. LaRosa GJ, Horvath C, Newman W, Jones T, O'Brien SH, O'Keefe T. (2004)
Humanized anti-CCR2 antibodies and methods of use therefor.
Patent number: US6696550 B2. Assignee: Millennium Pharmaceuticals, Inc.. Priority date: 23/07/1998. Publication date: 24/02/2004.